Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis

  • Monreal, Enric|||0000-0003-3293-0125
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Sainz De La Maza, Susana
  • Espiño, Mercedes
  • Villarrubia, Noelia
  • Roldán, Ernesto
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Cuello, Juan Pablo
  • Ayuso-Peralta, Lucía
  • Rodero-Romero, Alexander
  • Chico-García, Juan Luís
  • Rodríguez-Jorge, Fernando
  • Quiroga-Varela, Ana
  • Rodríguez-Martín, Eulalia
  • Pilo, Belén
  • Martín Ávila, Guillermo
  • Martínez Ginés, María Luisa
  • García Domínguez, José Manuel
  • Rubio, Lluïsa
  • Llufriu, Sara|||0000-0003-4273-9121
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montalban, Xavier|||0000-0002-0098-9918
  • Álvarez Bravo, Gary|||0000-0003-0342-0177
  • Veiga-Gonzalez, José Luis
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M.|||0000-0002-9067-3668
The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB-positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB-negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Monreal, Enric|||0000-0003-3293-0125
  • Medina, Silvia|||0000-0002-6051-173X
  • Quintana, Ester|||0000-0001-8885-1931
  • Sainz de la Maza, Susana|||0000-0001-8605-0049
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Lapuente, Paloma
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Montalban, Xavier|||0000-0002-0098-9918
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Carrasco-Sayalero, Angela
  • Rodríguez-Martín, Eulalia
  • Roldán, Ernesto
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M|||0000-0002-9067-3668
UDHEBRON, To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​